The Ritedose Corporation

Earlier this year, the US Congress introduced the BIOSECURE Act, a proposed law that would prevent US pharmaceutical companies from engaging with Chinese CDMOs. The bill (which is still in Congress) was quickly introduced in reaction to US intelligence agency reports claiming that the giant Chinese CDMO, WuXi Apptec, had given information to the Chinese government about its American business clients. WuXi once was involved in one quarter of commercial drug manufacturing in the US; now its US activities are ending. Meanwhile, drug manufacturing must continue, in the face of this significant uncertainty. Where can you take your CDMO business? This LabBiotech.eu article provides more background, and some possibilities for filling a $5 billion gap. IOHO, Ritedose is the "rite" solution. We’re U.S.-based, and our customers have placed their trust in us for more than 25 years. In fact, we have a 100% client retention. In addition, we have the regulatory expertise to monitor pending legislation like the BIOSCURE Act. Learn what we can do for you: www.ritedose.com.

We wouldn't be the company we are today without the dedication and support of our team. Thanks for all you do to make Ritedose a GREAT place to work! Last week, we thanked this incredible teams by treating them to lunch!

The American Heart Association named Ritedose the #1 AHA fundraising company for 2023. But our team didn’t stop there. This year at Ritedose’s Field Day, we raised more than $77,000—double last year’s achievement. As part of their dedication to working with our community, 205 employees in 22 teams competed in exercises, games and educational activities to raise money to support efforts to end stroke and heart disease. Learn more about how we’ve worked with the AHA here: https://lnkd.in/e6WFgVYf. 

We're #hiring a new Mechanical Engineer- Facilities in Columbia, South Carolina Metropolitan Area. Apply today or share this post with your network.

According to the analytics firm Evaluate Ltd, the growth of Contract Development and Manufacturing Organizations (CDMOs) like Ritedose will likely outpace all pharmaceutical company growth through 2028. Contract manufacturers are now regularly seen as key partners in creating and scaling up the manufacture of therapeutics efficiently, safely, and cost-effectively. At Ritedose, we're embracing these partnerships. Working together with our customers, we're advancing therapeutics, developing more trust and developing new production techniques. The predictions, published in Fierce Pharma, traces this growth back to the COVID-19 pandemic and the sudden, acute need for new vaccines and other therapeutics. At Ritedose, we too are seeing these trends continue as pharmaceutical developers and manufacturers realize the value of a trusted CDMO partner. In fact, we're expanding our manufacturing capacity to produce therapeutics safely, securely, and aseptically. Find out more about Ritedose’s work here: https://ritedose.com/cdmo/.

Being part of Ritedose is more than just being the among best at what you do. For us, it means being part of a culture and community that builds, and people who join our team need to know that there’s nothing more important to us than the communities we work in and live in. Becoming a part of the team at Ritedose isn’t a job. It’s a commitment. It’s about being committed to quality, accountability, and being part of a team that can always rely on each other. Looking to be part of a team like that? Check out our opportunities at https://lnkd.in/gajnDNYq.

What does the future of drug manufacturing look like? What can a CDMO do to  manage the quickly changing landscape of pharmaceuticals? In this Endpoints News webinar, Alessandro Maselli, CEO of Catalent Pharma Solutions, talks with editor John Carroll about: -- Stability, trust and growth management that come from working with CDMOs -- What’s changing in the CDMO industry (consolidation, innovations, NDAs) -- The effect of “reshoring” from Asia to the US and/or Europe, thanks to the BIOSECURE Act and other factors At Ritedose, we can help you manage growth and deal with the changing CDMO climate! Watch the webinar recording: https://lnkd.in/e7z6BP6u

Looking to scale up your therapeutic manufacturing capacity? Will only the best in sterile processing be enough? At Ritedose, we take aseptic, efficient and excellent CDMO processes to heart, from clinical trial transition to BFS to fill and finish. Visit our website at ritedose.com and find out what we can do for you today!

Did you know about BFS? BFS—blow-fill-seal technology—is taking the pharmaceutical world by storm. Already, its market value is in excess of $3.2 billion, that market is expected to grow by 6.8 percent (CAGR) through 2033, where it’s estimated to total $6.2 billion.  Blow-fill-seal is The Ritedose Corporation’s key technology for drug manufacturing. It alleviates concerns about human error and interventions, and operates in a nearly 100 percent sterile process and environment. Plus, it’s simple and efficient. In fact, we recently announced we are expanding our BFS capabilities by 180-million-units for ophthalmic and respiratory medications. So, how does BFS work? BFS is used to make pre-measured, single-dose pharmaceutical products. With no human contact, a container is formed (blow), filled with product and then sealed, ready for delivery to patients. Blow—the container is formed by forcing the container material (which could be polymer plastic resins, or, less commonly, glass) into a mold, creating the container’s shape.  Fill—then, the container is filled with the drug product. Each dose is pre-measured according to the container size. Seal—the processor then closes off the top of the container, creating a secure seal and ensuring a sterile product. This tab that creates the seal can be easily twisted off when ready to dispense. Simple enough! Contact Ritedose to find out more about our BFS processes: https://ritedose.com/.

We're #hiring a new System Engineer (MES) in Columbia, South Carolina. Apply today or share this post with your network.